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Most women facing gynecologic cancer live in coun-
tries with inadequate health systems, and treatment is
rarely in line with international standards. This is
particularly true in cervical cancer, because most
developing countries offer few opportunities for ra-
diotherapy, leaving many women without proper
treatment and the risk of avoidable mortality.1 The
Lancet recently highlighted the need to close the
global cancer divide for women, but real progress will
require not only evidence-based policy making but
also broad multisectoral collaboration and innovative
public health approaches to cancer care and control.2
The gynecologic malignancy with the highest cure rate
is gestational trophoblastic neoplasia (GTN). Post-
molar GTN was studied at the Mansoura University
Hospital, Mansoura, Egypt, with support from the
Erasmus MC Cancer Institute, University Medical
Center, Rotterdam, the Netherlands. The outcome of
this study has implications for all women with GTN,
and we would therefore like to share our experiences
and at the same time advocate for an increase in
worldwide partnerships of researchers to improve our
understanding of routine clinical problems.
Outcome of the Study From an International Perspective
In a randomized controlled trial, we studied the ef-
fects of second curettage in postmolar GTN on the
number of methotrexate chemotherapy courses and
found that a second curettage did not reduce the
number of courses needed to normalize serum hu-
man chorionic gonadotropin (hCG) levels.3 Simulta-
neously, a multicenter prospective phase II study on
the curative effect of recurettage in a similar patient
group, performed in North America by the Gyneco-
logic Oncology Group (GOG), showed that a second
curettage cured 40% of women with postmolar GTN.4
Although the studies had different end points, we can
conclude that second curettage is of value only
when cure (ie, normalization of hCG) is expected.
Together, the results of these studies ﬁnally settle the
question of the role of second uterine curettage in
postmolar GTN.
Available Collaborations
After the formation of the Gynecologic Cancer In-
terGroup, the number of high-quality phase III trials at
the global level has increased. However, most of the
involved centers originate in developed countries. On
meta-analysis of the global patterns of collaboration,
most authors were found to be from larger centers in
the northern and western United States and in
Europe.5 Developing nations face many health chal-
lenges and lack the science, equipment, and ﬁnancial
infrastructure needed for research. Cooperation be-
tween the developing and the developed world is
therefore mandatory.6 The beneﬁts of collaborative
projects extend well beyond scientiﬁc value alone. In
this essay, we would like to emphasize several of these
soft aspects.
Some Studies Are Challenging in the
Developed World
Certain studies cannot be efﬁciently carried out in
developed countries because of low disease incidence
and decentralized treatment; a case in point is GTN.
The difﬁculty in patient accrual is reﬂected in our
study3 and the GOG study4; in the GOG study, 9
centers recruited 64 patients over a period of 5.5
years, whereas the single-center Egyptian study
recruited 89 patients in 4 years, indicating that in-
ternational collaboration can sometimes overcome
problems of slow patient recruitment.6
Collaboration Improves the Standard of Care in
Low-Income Countries
Health care beneﬁts that may arise from contribution
to clinical research include improvements in the local
infrastructure, processes of care, and workforce.7 As
a result of our involvement in the GTN study,3 practice
at Mansoura Hospital has been evaluated and pro-
tocols updated in line with international standards.
Other spinoffs of this collaboration include the launch
of the ﬁrst trophoblast clinic in Egypt, which now serves
as a referral center for patients in the wider area, and
the development in Arabic of a patient information
leaﬂet on molar pregnancy. The trophoblast clinic has
also established collaborations with sponsors to ensure
that care remains available and is provided free of
charge. Furthermore, this center recognized that re-
current mole (ie, ≥ 3 episodes of molar pregnancy)
occurs more frequently than expected in the Egyptian
Nile Delta (incidence ﬁgures not yet available).
Moreover, collaboration with international experts was
sought and chromosomal analyses performed, free of
charge, in selected cases. This analysis resulted in the
detection of mutations in several patients with re-
current molar pregnancies and led to the discovery of
a recently published novel mutation.8,9
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Collaboration Improves the Standard of Research in
Low-Income Countries
Through these alliances, colleagues who are unfamiliar with
research practice are encouraged to adhere to international
standards, beginning with a well-thought-out research pro-
tocol and proper recording of data, preferably using an
electronic case record form. By engaging the resources of the
supporting parties, such as Internet-based randomization
programs and access to international literature, the research
capacity of colleagues in a low-resource setting can be sig-
niﬁcantly enhanced. Collaborative analysis of data also allows
for a better recognition of possible biases and weaknesses of
a study. The knowledge obtained through hands-on support
can be transferred to other researchers and staff members,
further enhancing the positive effects of a collaborative study.
In the case of this particular study, the sharing of results via
a consensus workshop on gestational trophoblastic tumors
has allowed us to reach gynecologists, pathologists, and
oncologists all over Egypt. Finally, the presentation of results at
international meetings and publication in high-impact journals
beneﬁt all researchers concerned.
Collaboration Improves Mutual Understanding
Persistent GTN is one of the few neoplasias with a high
cure rate, when treated appropriately. However, col-
leagues in low-resource countries often encounter prob-
lems unimaginable for professionals in the developed
world. A range of challenges can frustrate effective
treatment. For example, economic and political issues
may obstruct patient travel to clinics for appointments,
with resulting unwelcome delays in treatment. Some of
these problems are gender related,10 whereas others re-
quire adaptations of research protocols to local situations.11
Women are more likely to be illiterate than men, and in-
formation given to the family may not always be shared
with the patient. In many developing countries, women
cannot or are not permitted by cultural norms to travel by
themselves and therefore rely on a spouse or male family
member to reach the hospital. Alternatively, women can be
treated at home, an approach that might also be of value for
women in the developed world, who at present have to
visit a clinic for methotrexate injections 4 times within 8
days, repeated each cycle. Considerable time and expense
might be spared if injections could be administered closer
to home.
Given the many different national laws and regulations,
performing international studies is challenging and costly.
However, by performing similar, concurrent studies in
multiple countries and uniting the outcomes of the
various study sites, this disadvantage can be partly
counterbalanced.6,11,12 Organizations such as the In-
ternational Society for the Study of Trophoblastic Disease
could take the lead in establishing these collaborations.
Collaboration Is Fun
Last but not least, although international collaborations in
which experienced researchers support colleagues in less
fortunate circumstances certainly present many chal-
lenges, these partnerships can also be both valuable and
enjoyable. Collaboration improves local care, offers pro-
fessional satisfaction, and ultimately provides answers to
shared scientiﬁc and clinical problems.
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